Aquestive Therapeutics, Inc. (AQST) financial statements (2020 and earlier)

Company profile

Business Address 30 TECHNOLOGY DRIVE
WARREN, NJ 07059
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2161
Cash and cash equivalents2161
Receivables10
Inventory, net of allowances, customer advances and progress billings45
Inventory45
Deferred costs 5
Other undisclosed current assets123
Total current assets:3874
Noncurrent Assets
Property, plant and equipment1012
Intangible assets, net (including goodwill)00
Intangible assets, net (excluding goodwill)00
Other noncurrent assets00
Total noncurrent assets:1113
TOTAL ASSETS:4987
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1928
Accounts payable1420
Accrued liabilities17
Employee-related liabilities3 
Taxes payable0 
Other undisclosed accounts payable and accrued liabilities0 
Deferred revenue1
Debt 5
Other undisclosed current liabilities 1
Total current liabilities:2033
Noncurrent Liabilities
Long-term debt and lease obligation6043
Long-term debt, excluding current maturities6043
Liabilities, other than long-term debt31
Deferred revenue2
Asset retirement obligations11
Total noncurrent liabilities:6344
Total liabilities:8377
Stockholders' equity
Stockholders' equity attributable to parent(34)10
Common stock00
Additional paid in capital8371
Accumulated deficit(118)(61)
Total stockholders' equity:(34)10
TOTAL LIABILITIES AND EQUITY:4987

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
Gross profit:5367
Operating expenses(108)(116)
Operating loss:(55)(49)
Nonoperating expense
(Other Nonoperating expense)
 (0)
Interest and debt expense(13)(8)
Other undisclosed loss from continuing operations before equity method investments, income taxes(0) 
Loss from continuing operations before equity method investments, income taxes:(68)(57)
Other undisclosed income (loss) from continuing operations before income taxes1(5)
Net loss available to common stockholders, diluted:(68)(61)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
Net loss:(68)(61)
Comprehensive loss, net of tax, attributable to parent:(68)(61)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: